Cochlear Limited (ASX: COH) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Cochlear Limited Chart and Price Data
Fundamentals Data provided by Morningstar.
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Cochlear Limited (ASX: COH)
Latest News
Healthcare Shares
Why is the Cochlear (ASX:COH) share price tumbling 5% on Thursday?
Broker Notes
Top brokers name 3 ASX shares to buy today
Broker Notes
Here are the latest broker updates from Macquarie. It's not all pretty for ASX shares.
Broker Notes
Leading brokers name 3 ASX shares to sell today
Healthcare Shares
Cochlear (ASX:COH) share price higher on FDA approval
Healthcare Shares
Hear this: Why the Cochlear (ASX:COH) share price had such a difficult time in 2021
Healthcare Shares
Where are Cochlear (ASX:COH) shares headed in 2022?
Blue Chip Shares
2 ASX 50 shares to buy in 2022
Healthcare Shares
What's the outlook for ASX healthcare shares in 2022?
Broker Notes
Why this top broker says the Cochlear (ASX:COH) share price is heading lower
Healthcare Shares
With restrictions easing, is the Cochlear (ASX:COH) share price a buy?
Growth Shares
3 ASX 200 shares with major competitive advantages
Frequently Asked Questions
-
Yes, Cochlear Ltd has historically paid two fully franked dividends a year.
-
Cochlear Ltd generally pays its dividends in April and October.
-
Cochlear Ltd listed on the ASX on 4 December 1995.
COH ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Cochlear Limited
Cochlear Ltd (ASX: COH) is the world's leading cochlear implant device manufacturer with around half of global market share.
The company was founded in Australia in 1983 to commercialise implants pioneered by Melbourne researcher Dr Graeme Clark, but later became a separate entity.
Developed markets contribute the bulk of Cochlear's group revenue with cochlear implants the standard of care for children with severe to profound hearing loss. The company is also catering for a growing cohort of seniors when standard hearing aid technology loses its effectiveness.
Cochlear's main products include cochlear implants, bone-anchored hearing devices, and associated sound processors. The vast majority of Cochlear's revenue is derived from overseas, with the US and Europe by far the company's two largest markets.
